For example, two antibodies, cetuximab 137 and panitumumab 138, have been explored preclinically, both targeting the epidermal growth factor receptor (EGFR), also known as HER1, which is found to be overexpressed in several cancers. The gene discussed is EGFR; the disease is cancer.